• 1
    Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711723.
  • 2
    Lens M, Ferrucci PF, Testori A. Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings. Recent Pat Anticancer Drug Discov. 2008; 3: 105113.
  • 3
    Margolin K. Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma. Commun Oncol. 2008; 5: 367374.
  • 4
    Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010; 37: 499507.
  • 5
    Bristol-Myers Squibb. YERVOY (ipilimumab) summary of product characteristics. Braine-l'Alleud, Belgium: Bristol-Myers Squibb; 2011. Available at: Accessed January 13, 2013.
  • 6
    O'Day S, Weber JS, Wolchok JD, et al. Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies [abstract]. J Clin Oncol. 2011; 28( suppl). Abstract 8554.
  • 7
    Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006; 24: 22832289.
  • 8
    Harmankaya K, Erasim C, Koelblinger C, et al. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than 2 years following ipilimumab therapy. Med Oncol. 2010; 28: 11401144.
  • 9
    Lorigan P, Sosman J, Haanen JB, et al. Clinical response to ipilimumab: effect of systemic corticosteroids used to manage immune-related adverse events (irAEs) [abstract]. Ann Oncol. 2010; 21: viii404. Abstract 1331P.
  • 10
    Hinrichs CS, Palmer DC, Rosenberg SA, Restifo NP. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J Immunother. 2005; 28: 517524.
  • 11
    Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann N Y Acad Sci. 2004; 1024: 124137.
  • 12
    Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012; 13: 459465.
  • 13
    Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012; 30: 26912697.
  • 14
    Lebbe C, O'Day SJ, Chiarion-Sileni V, et al. Analysis of the onset and resolution of immune-related adverse events during treatment with ipilimumab in patients with metastatic melanoma [abstract]. Paper presented at: Perspectives in Melanoma XII; October 2-4, 2008; Scheveningen/The Hague, Netherlands. Oral Abstract O-015.
  • 15
    Kahler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges. 2011; 9: 277286.
  • 16
    Klein O, Ebert LM, Nicholaou T, et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res. 2009; 15: 25072513.
  • 17
    Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma [serial online]. Cancer Immun. 2010; 10: 11.
  • 18
    Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006; 212: 256271.
  • 19
    Sarnaik AA, Yu B, Yu D, et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2011; 17: 896906.
  • 20
    Lin R, Yellin MJ, Lowy I, Safferman A, Chin K, Ibrahim R. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: prevention of gastrointestinal perforation and/or colectomy [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 9063.